GenrAb Developing a Multiple Sclerosis Antibody

A generation ago, a multiple sclerosis diagnosis often meant a gradual decline in quality of life. This autoimmune disease, affecting nearly a million people in the U.S., attacks myelin—the protective coating around nerves—leading to debilitating symptoms like fatigue, muscle weakness, and difficulty walking. While advances in treatment have helped many manage symptoms and maintain active lives, there is still no cure.

At Dallas' Pegasus Park biotech hub, emerging biopharmaceutical company GenrAb is developing a promising breakthrough—an antibody designed to protect cells from the damage caused by this neurological disease.

Learn more